# Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age

> **NCT05741476** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **DBV Technologies** · enrollment: 600 (estimated)

## Conditions studied

- Allergy, Peanut

## Interventions

- **DRUG:** DBV712
- **OTHER:** Placebo
- **DRUG:** DBV712

## Key facts

- **NCT ID:** NCT05741476
- **Lead sponsor:** DBV Technologies
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-02-21
- **Primary completion:** 2025-11-06
- **Final completion:** 2029-10
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2026-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05741476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05741476, "Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT05741476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*